Project Grant R15HL175648
Award Date 9/15/25
Completion Date 8/31/28
Dollars Obligated $406K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- This $500,000 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of the Hemotago HATS-OFF (Hemotag Assessment for Short-Term Outcomes of Heart Failure) technology by Aventusoft LLC, a small disadvantaged business in Boca Raton, Florida. The HATS-OFF system provides a non-invasive, at-home method for long-term monitoring of heart failure patients to detect decompensation early and enable timely therapy...
- The University of Pittsburgh was awarded a $300,000 federal Project Grant from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on "REAL-TIME EVALUATION OF ACUTE MYOCARDIAL INFARCTION WITH MULTI-LEAD ECG MONITORING FROM WEARABLE PPG MEASUREMENTS". The grant, awarded on September 15, 2025, will support the university's research efforts to advance the scientific understanding of cardiovascular health through the...
- This $702,534 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Texas A&M Engineering Experiment Station (Tees) to develop an integrated super-resolution cardiac magnetic resonance imaging-deep learning (CMR-DL) technology. The goal is to isolate and quantify the contributions of passive and active mechanisms to impaired left ventricular relaxation, a key driver of left ventricular diastolic dysfunction...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Safebeat RX Inc. The funding supports the development of a novel, smartwatch-enabled technology that allows patients with low-risk atrial fibrillation to safely initiate antiarrhythmic medications at home. The technology analyzes post-drug ECG data taken by patients using a machine learning algorithm and provides this information to...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), has awarded a $522,695 Project Grant to Kennesaw State University (KSU) to develop and validate a generative AI framework that can efficiently and accurately predict the biomechanical outputs of the bi-ventricular myocardium. The 3-year project aims to enhance personalized diagnosis and treatment of ventricular diseases, such as hypertrophic cardiomyopathy, heart failure,...
- This federal Project Grant award of $429,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a study to investigate the impact of selective vagal neuromodulation on heart failure indices. The 2-year project, with a start date of September 1, 2025, will be conducted by the University of Colorado-Denver. The research aims to better understand the neural interface by studying the effects of selective activation of cholinergic (efferent)...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $429,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Michigan Technological University. The funding supports research to improve patient selection and left ventricular lead placement for cardiac resynchronization therapy (CRT) by integrating analysis of electrical dyssynchrony on ECG and mechanical dyssynchrony on gated SPECT myocardial perfusion imaging. The project aims to use unsupervised...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to discover novel biomarkers and biological mechanisms underlying early-stage heart failure (HF). The $147,486 award to Duke University will support the development of an automated computational phenotype to identify early-stage HF, which will then be applied to large population cohorts. The research aims to leverage multi-omics data integration and...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $349,734 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Actiox LLC, a biomedical technology company in Thousand Oaks, California. The project aims to develop a wearable microneedle-based biosensor for continuous, real-time cardiac troponin I monitoring. The goal is to demonstrate the feasibility of this transformative biosensor technology to enable earlier detection of ischemic events and...